NCT04713982 · Phase 2 · ACTIVE NOT RECRUITING
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
This trial is testing whether deutetrabenazine, a drug already used to reduce involuntary movements in Huntington's disease, also improves how patients speak and walk. Researchers will measure changes in speech quality and gait patterns over the course of treatment. This is a Phase 2 trial, meaning scientists are still gathering evidence on whether it works and how safe it is — it is not yet proven or approved for these specific symptoms.
You may qualify if
- Diagnosis of HD with documented CAG repeat ≥ 37
- UHDRS total maximal chorea score of ≥ 8
- Able to walk at least 10 meters
- Medically stable outpatient, based on the investigator's judgment
- Willing and able to give written informed consent prior to performing any study procedures
- Have completed at least 10th grade
- Montreal Cognitive Assessment score ≥ 22 on screening
- Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion
You're excluded if
- Severe depression or suicidal ideation
- History of suicidal behavior
- Unstable or serious medical or psychiatric illness
- Renal or hepatic impairment
- Severe speech impairment or anarthria
- Inability to swallow study medication
- Women who are pregnant or breast feeding
- History of alcohol or substance abuse within the last 12 months
- Current use of VMAT2 inhibitor (tetrabenazine, deutetrabenazine, valbenazine)
- Concurrent participation in any other investigational drug trials
- EKG QTcF> 500 mse
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-14